KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $2.7 billion.

  • Takeda Pharmaceutical's Free Cash Flow fell 444.56% to $2.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.5 billion, marking a year-over-year decrease of 249.21%. This contributed to the annual value of $6.6 billion for FY2025, which is 2829.49% up from last year.
  • According to the latest figures from Q4 2025, Takeda Pharmaceutical's Free Cash Flow is $2.7 billion, which was down 444.56% from $2.8 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's Free Cash Flow's 5-year high stood at $3.9 billion during Q1 2021, with a 5-year trough of $129.6 million in Q1 2025.
  • Over the past 5 years, Takeda Pharmaceutical's median Free Cash Flow value was $1.8 billion (recorded in 2022), while the average stood at $2.0 billion.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 70304.68% in 2021, then crashed by 8898.09% in 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Free Cash Flow (Quarter) stood at $3.3 billion in 2021, then decreased by 11.57% to $2.9 billion in 2022, then tumbled by 55.07% to $1.3 billion in 2023, then surged by 115.45% to $2.8 billion in 2024, then fell by 4.45% to $2.7 billion in 2025.
  • Its Free Cash Flow was $2.7 billion in Q4 2025, compared to $2.8 billion in Q3 2025 and $1.8 billion in Q2 2025.